Protein or Polypeptide-Loaded Extracellular Vesicle Delivery Platform and Application Thereof
Summary
USPTO published patent application US20260108470A1 on April 23, 2026, disclosing a plasmid combination for preparing extracellular vesicles loaded with target proteins or polypeptides, including cGAS and Cre gene plasmids. The application, filed on December 21, 2025 (Application No. 19428281), also covers the extracellular vesicles loaded with these proteins and their use in cancer prevention or treatment. Inventors are Linzhao Cheng, Senquan Liu, and Ding Ma.
“An application of the extracellular vesicle in the prevention or treatment of a cancer is further provided.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 193 changes logged to date.
What changed
USPTO published patent application US20260108470A1 on April 23, 2026, disclosing a plasmid combination (pCAG-GOI plasmid and pMD2.G plasmid) for preparing extracellular vesicles loaded with target proteins or polypeptides. The application specifically covers extracellular vesicles loaded with cyclic GMP-AMP synthase (cGAS) and cyclization recombinase (Cre) for cancer prevention or treatment.
Competitors in the biotech and pharmaceutical sectors should note this publication as potential prior art. Third parties developing similar extracellular vesicle delivery technologies for therapeutic applications may need to assess potential overlap with the claimed plasmid combination and therapeutic uses.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PROTEIN OR POLYPEPTIDE-LOADED EXTRACELLULAR VESICLE DELIVERY PLATFORM AND APPLICATION THEREOF
Application US20260108470A1 Kind: A1 Apr 23, 2026
Inventors
Linzhao CHENG, Senquan LIU, Ding MA
Abstract
A plasmid combination for preparing an extracellular vesicle loaded with a target protein or polypeptide, including a pCAG-GOI plasmid and a pMD2.G plasmid, where GOI refers to a gene sequence corresponding to the target protein or the polypeptide. The pCAG-GOI plasmid is a pCAG-cyclic GMP-AMP synthase (cGAS) gene plasmid, a pCAG-cyclization recombinase (Cre) gene plasmid and a combination thereof. An extracellular vesicle loaded with cyclic GMP-AMP synthase, cyclization recombinase or a combination thereof is provided, which is prepared by transfecting a cell with the plasmid combination. An application of the extracellular vesicle in the prevention or treatment of a cancer is further provided.
CPC Classifications
A61K 9/5068 A61K 38/45 A61K 39/3955 A61P 35/00 C12N 5/0686 C12N 9/1241 C12N 15/85 A61K 2039/505 C12N 2510/00
Filing Date
2025-12-21
Application No.
19428281
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.